-
May 29, 2024 | 
onclive.com | Milind M. Javle |Rachna T Shroff |Steven West
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give BirthHPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age
-
Jun 20, 2023 | 
onclive.com | Milind M. Javle |Laura W. Goff
What is the Role of Biomarker Testing in Biliary Tract Cancers? Shared insight on the role of molecular testing in the diagnosis of biliary tract cancers and how it may inform the selection of optimal therapy.
-
Jun 20, 2023 | 
onclive.com | Milind M. Javle |Laura W. Goff
Expert oncologists Milind Javle, MD, and Laura Goff, MD, reflect on the subsets of biliary tract cancers and consider best practices in making an accurate diagnosis.
-
Mar 22, 2023 | 
onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha
Transcript:Milind M. Javle, MD: For our closing remarks, let me start with you, Dr Rocha. Given these strategies and findings in biliary tract cancer, what are you excited about and what are you looking forward to? Flavio G. Rocha, MD, FACS, FSSO: Thank you, Dr Javle. I’m very excited. All these developments that we see—in the advanced setting, the targeted setting, and the mutational landscape—I want to bring up front.
-
Mar 22, 2023 | 
onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha
Transcript:Milind M. Javle, MD: Inthe final segment of this program, we’re going to talk about targeted therapy. Dr Shroff, the last few years have been exciting, with 4 agents approved: infigratinib, pemigatinib, futibatinib, and ivosidenib. Perhaps there are more to come in the next year or 2. This is quite a staggering trajectory. Could you reflect on the FGFR space? There appears to be some redundancy and overlap in this space. What are you looking forward to?
-
Mar 15, 2023 | 
onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha
OncologyLiveOncology FellowsSupplements And Featured PublicationsAll Publications
-
Mar 8, 2023 | 
onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha
Transcript:Milind M. Javle, MD: I’m going to move on to systemic therapy for advanced and resectable disease. Dr Shroff, you led the SWOG S1815 trial. It was a pioneering trial because it was the first randomized phase 3 trial in this space. We’ve been eagerly anticipating the result. You gave a presentation [at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, ASCO GI].
-
Mar 8, 2023 | 
onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha
Transcript:Milind M. Javle, MD: Dr Rocha, the ultimate local therapy, liver transplant, is an accepted modality for the other liver cancer, HCC [hepatocellular carcinoma]. But I recall the original Milan criteria in NEJM [New England Journal of Medicine], which reflected on the fact that HCC used to be a contraindication for liver transplants sometime ago. There has been a sea change in cholangiocarcinoma as well. Could you comment on hilar cholangiocarcinoma and your experience there? Flavio G.
-
Mar 1, 2023 | 
onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha
Transcript:Milind M. Javle, MD: I’m going to switch gears slightly. Dr Koay, and perhaps Dr Rocha as well, there are a variety of liver-directed therapies, and it’s quite confusing which way to go. There’s radioembolization, radiation therapy, radiofrequency ablation. Some places are also doing chemoembolization. How do we choose which is the appropriate modality?
-
Mar 1, 2023 | 
onclive.com | Milind M. Javle |Eugene J. Koay |Rachna T Shroff |Flávio Rocha
Transcript:Milind M. Javle, MD: Why are we talking about surgical resection? It turns out, Dr Rocha, that this patient is surgically resectable, but unfortunately, the risk of recurrence is too high. Could you highlight what your approach is and how this has changed over the years for surgical as well as perioperative therapy? Flavio G. Rocha, MD, FACS, FSSO: Yes. These hilar cholangiocarcinomas are probably the most challenging operation that we do in the abdomen.
